{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:56:26Z","timestamp":1792446986822,"version":"4.5.0"},"reference-count":70,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2023,3,21]]},"abstract":"<jats:p>Background: Astrocyte reactivity is an early event along the Alzheimer\u2019s disease (AD) continuum. Plasma glial fibrillary acidic protein (GFAP), posited to reflect astrocyte reactivity, is elevated across the AD continuum from preclinical to dementia stages. Monoamine oxidase-B (MAO-B) is also elevated in reactive astrocytes observed using 18F-SMBT-1 PET in AD. Objective: The objective of this study was to evaluate the association between the abovementioned astrocyte reactivity biomarkers. Methods: Plasma GFAP and A\u03b2 were measured using the Simoa\u00ae platform in participants who underwent brain 18F-SMBT-1 and A\u03b2\u2013PET imaging, comprising 54 healthy control (13 A\u03b2\u2013PET+ and 41 A\u03b2\u2013PET\u2013), 11 mild cognitively impaired (3 A\u03b2\u2013PET+ and 8 A\u03b2\u2013PET\u2013) and 6 probable AD (5 A\u03b2\u2013PET+ and 1 A\u03b2\u2013PET\u2013) individuals. Linear regressions were used to assess associations of interest. Results: Plasma GFAP was associated with 18F-SMBT-1 signal in brain regions prone to early A\u03b2 deposition in AD, such as the supramarginal gyrus (SG), posterior cingulate (PC), lateral temporal (LT) and lateral occipital cortex (LO). After adjusting for age, sex, APOE \u025b4 genotype, and soluble A\u03b2 (plasma A\u03b242\/40 ratio), plasma GFAP was associated with 18F-SMBT-1 signal in the SG, PC, LT, LO, and superior parietal cortex (SP). On adjusting for age, sex, APOE \u025b4 genotype and insoluble A\u03b2 (A\u03b2\u2013PET), plasma GFAP was associated with 18F-SMBT-1 signal in the SG. Conclusion: There is an association between plasma GFAP and regional 18F-SMBT-1 PET, and this association appears to be dependent on brain A\u03b2 load.<\/jats:p>","DOI":"10.3233\/jad-220908","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T13:06:11Z","timestamp":1676034371000},"page":"615-628","source":"Crossref","is-referenced-by-count":35,"title":["Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"92","author":[{"given":"Pratishtha","family":"Chatterjee","sequence":"first","affiliation":[{"name":"Macquarie Medical School, Macquarie University, North Ryde, NSW, Australia"},{"name":"School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and for the AIBL Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Dor\u00e9","sequence":"additional","affiliation":[{"name":"The Australian eHealth Research Centre, CSIRO, Brisbane, QLD, Australia"},{"name":"Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Pedrini","sequence":"additional","affiliation":[{"name":"School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia"},{"name":"Australian Alzheimer\u2019s Research Foundation, Sarich Neuroscience Research Institute, Nedlands, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Krishnadas","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia"},{"name":"The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohith","family":"Thota","sequence":"additional","affiliation":[{"name":"Macquarie Medical School, Macquarie University, North Ryde, NSW, Australia"},{"name":"School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierrick","family":"Bourgeat","sequence":"additional","affiliation":[{"name":"Health and Biosecurity Flagship, Australian eHealth Research Centre, Herston, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos D.","family":"Ikonomovic","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA"},{"name":"Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie R.","family":"Rainey-Smith","sequence":"additional","affiliation":[{"name":"School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia"},{"name":"Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA, Australia"},{"name":"Australian Alzheimer\u2019s Research Foundation, Sarich Neuroscience Research Institute, Nedlands, WA, Australia"},{"name":"School of Psychological Science, University of Western Australia, Crawley, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha C.","family":"Burnham","sequence":"additional","affiliation":[{"name":"Health and Biosecurity Flagship, Australian eHealth Research Centre, Herston, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Fowler","sequence":"additional","affiliation":[{"name":"The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Taddei","sequence":"additional","affiliation":[{"name":"School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia"},{"name":"Australian Alzheimer\u2019s Research Foundation, Sarich Neuroscience Research Institute, Nedlands, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Mulligan","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ames","sequence":"additional","affiliation":[{"name":"National Ageing Research Institute, Parkville, VIC, Australia"},{"name":"Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin L.","family":"Masters","sequence":"additional","affiliation":[{"name":"The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Fripp","sequence":"additional","affiliation":[{"name":"The Australian eHealth Research Centre, CSIRO, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia"},{"name":"The Florey Department of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph N.","family":"Martins","sequence":"additional","affiliation":[{"name":"Macquarie Medical School, Macquarie University, North Ryde, NSW, Australia"},{"name":"School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia"},{"name":"Australian Alzheimer\u2019s Research Foundation, Sarich Neuroscience Research Institute, Nedlands, WA, Australia"},{"name":"School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor L.","family":"Villemagne","sequence":"additional","affiliation":[{"name":"Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia"},{"name":"Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-220908_ref1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.3233\/JAD-220908_ref2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220908_ref3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220908_ref4","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.3233\/JAD-220908_ref5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: A new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-220908_ref6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13195-020-00682-7","article-title":"Combination of plasma amyloid beta(1-42\/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology","volume":"12","author":"Verberk","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220908_ref7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease","volume":"11","author":"Chatterjee","year":"2021","journal-title":"Transl Psychiatry"},{"key":"10.3233\/JAD-220908_ref8","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer\u2019s disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"10.3233\/JAD-220908_ref9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41593-020-00783-4","article-title":"Reactive astrocyte nomenclature, definitions, and future directions","volume":"24","author":"Escartin","year":"2021","journal-title":"Nat Neurosci"},{"key":"10.3233\/JAD-220908_ref10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1440-1819.1998.tb02706.x","article-title":"A quantitative study of neurofibrillary tangles, senile plaques and astrocytes in the hippocampal subdivisions and entorhinal cortex in Alzheimer\u2019s disease, normal controls and non-Alzheimer neuropsychiatric diseases","volume":"52","author":"Muramori","year":"1998","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.3233\/JAD-220908_ref11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.neurobiolaging.2013.09.035","article-title":"Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer\u2019s disease","volume":"35","author":"Kamphuis","year":"2014","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-220908_ref12","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12724"},{"key":"10.3233\/JAD-220908_ref13","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-220908_ref14","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/alz.12447","article-title":"Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer\u2019s disease","volume":"18","author":"Chatterjee","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220908_ref15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","article-title":"Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment","volume":"13","author":"Cicognola","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220908_ref16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2967\/jnumed.110.087031","article-title":"Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: A multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG","volume":"53","author":"Carter","year":"2012","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-220908_ref17","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/brain\/awv404","article-title":"Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer\u2019s disease","volume":"139","author":"Rodriguez-Vieitez","year":"2016","journal-title":"Brain"},{"key":"10.3233\/JAD-220908_ref18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2967\/jnumed.120.244400","article-title":"(18)F-SMBT-1: A selective and reversible PET tracer for monoamine oxidase-B imaging","volume":"62","author":"Harada","year":"2021","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-220908_ref19","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2967\/jnumed.121.263254","article-title":"First-in-humans evaluation of (18)F-SMBT-1, a novel (18)F-labeled monoamine oxidase-B PET tracer for imaging reactive astrogliosis","volume":"63","author":"Villemagne","year":"2022","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-220908_ref20","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.2967\/jnumed.121.263255","article-title":"Assessing reactive astrogliosis with (18)F-SMBT-1 across the Alzheimer disease spectrum","volume":"63","author":"Villemagne","year":"2022","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-220908_ref21","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1093\/brain\/aws125","article-title":"Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer\u2019s disease: A voxelwise PiB-PET longitudinal study","volume":"135","author":"Villain","year":"2012","journal-title":"Brain"},{"key":"10.3233\/JAD-220908_ref22","doi-asserted-by":"crossref","first-page":"e1512","DOI":"10.1212\/WNL.0000000000009216","article-title":"Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults","volume":"94","author":"Guo","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JAD-220908_ref23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0006-8993(97)01318-8","article-title":"Amyloid-beta peptide activates cultured astrocytes: Morphological alterations, cytokine induction and nitric oxide release","volume":"785","author":"Hu","year":"1998","journal-title":"Brain Res"},{"key":"10.3233\/JAD-220908_ref24","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0197-4580(01)00307-4","article-title":"Glial activation in Alzheimer\u2019s disease: The role of Abeta and its associated proteins","volume":"22","author":"Meda","year":"2001","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-220908_ref25","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/acel.12521","article-title":"Amyloid beta-induced astrogliosis is mediated by beta1-integrin via NADPH oxidase 2 in Alzheimer\u2019s disease","volume":"15","author":"Wyssenbach","year":"2016","journal-title":"Aging Cell"},{"key":"10.3233\/JAD-220908_ref26","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3233\/JAD-170819","article-title":"Alzheimer\u2019s disease, oligomers, and inflammation","volume":"62","author":"Forloni","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220908_ref27","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12879"},{"key":"10.3233\/JAD-220908_ref28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1017\/S1041610209009405","article-title":"The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer\u2019s disease","volume":"21","author":"Ellis","year":"2009","journal-title":"Int Psychogeriatr"},{"key":"10.3233\/JAD-220908_ref29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3233\/ADR-210005","article-title":"Fifteen years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and observations from 2,359 older adults spanning the spectrum from cognitive normality to Alzheimer\u2019s disease","volume":"5","author":"Fowler","year":"2021","journal-title":"J Alzheimers Dis Rep"},{"key":"10.3233\/JAD-220908_ref30","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.3233\/JAD-220908_ref31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: Clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-220908_ref32","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","article-title":"Mild cognitive impairment\u2013beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment","volume":"256","author":"Winblad","year":"2004","journal-title":"J Intern Med"},{"key":"10.3233\/JAD-220908_ref33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JAD-220908_ref34","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): Current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.3233\/JAD-220908_ref35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13550-018-0456-7","article-title":"Centiloid scaling for quantification of brain amyloid with [(18)F]flutemetamol using multiple processing methods","volume":"8","author":"Battle","year":"2018","journal-title":"EJNMMI Res"},{"key":"10.3233\/JAD-220908_ref36","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2967\/jnumed.115.171595","article-title":"Standardized expression of 18F-NAV4694 and 11C-PiB beta-amyloid PET results with the Centiloid scale","volume":"57","author":"Rowe","year":"2016","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-220908_ref37","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","article-title":"Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale","volume":"14","author":"Navitsky","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220908_ref38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220908_ref39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neuroimage.2018.08.044","article-title":"Implementing the centiloid transformation for (11)C-PiB and beta-amyloid (18)F-PET tracers using CapAIBL","volume":"183","author":"Bourgeat","year":"2018","journal-title":"Neuroimage"},{"key":"10.3233\/JAD-220908_ref40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","article-title":"Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology","volume":"15","author":"La Joie","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220908_ref41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","article-title":"Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease","volume":"13","author":"Jack","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220908_ref42","doi-asserted-by":"crossref","first-page":"e84777","DOI":"10.1371\/journal.pone.0084777","article-title":"MR-less surface-based amyloid assessment based on 11C PiB PET","volume":"9","author":"Zhou","year":"2014","journal-title":"PLoS One"},{"key":"10.3233\/JAD-220908_ref43","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1016\/j.neurobiolaging.2014.04.033","article-title":"Comparison of MR-less PiB SUVR quantification methods","volume":"36 Suppl 1","author":"Bourgeat","year":"2015","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-220908_ref44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13195-017-0324-0","article-title":"Oligomeric forms of amyloid-beta protein in plasma as a potential blood-based biomarker for Alzheimer\u2019s disease","volume":"9","author":"Wang","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220908_ref45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13195-021-00873-w","article-title":"Plasma amyloid-beta oligomerization assay as a pre-screening test for amyloid status","volume":"13","author":"Babapour Mofrad","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-220908_ref46","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-220908_ref47","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.25334","article-title":"Plasma amyloid as prescreener for the earliest Alzheimer pathological changes","volume":"84","author":"Verberk","year":"2018","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-220908_ref48","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/brain\/awx057","article-title":"Biochemically-defined pools of amyloid-beta in sporadic Alzheimer\u2019s disease: Correlation with amyloid PET","volume":"140","author":"Roberts","year":"2017","journal-title":"Brain"},{"key":"10.3233\/JAD-220908_ref49","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ana.24270","article-title":"Amyloid-beta efflux from the central nervous system into the plasma","volume":"76","author":"Roberts","year":"2014","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-220908_ref50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0306-4522(94)90311-5","article-title":"Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography","volume":"62","author":"Saura","year":"1994","journal-title":"Neuroscience"},{"key":"10.3233\/JAD-220908_ref51","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nm.3639","article-title":"GABA from reactive astrocytes impairs memory in mouse models of Alzheimer\u2019s disease","volume":"20","author":"Jo","year":"2014","journal-title":"Nat Med"},{"key":"10.3233\/JAD-220908_ref52","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1528-1157.1992.tb02336.x","article-title":"Invitro quantitative autoradiography of [3H]-L-deprenyl and [3H]-PK11195 binding sites in human epileptic hippocampus.","volume":"33","author":"Kumlien","year":"1992","journal-title":"Epilepsia"},{"key":"10.3233\/JAD-220908_ref53","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1093\/brain\/awx172","article-title":"Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders","volume":"140","author":"Tong","year":"2017","journal-title":"Brain"},{"key":"10.3233\/JAD-220908_ref54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF01245357","article-title":"Increased binding of 3H-L-deprenyl in spinal cords from patients with amyotrophic lateral sclerosis as demonstrated by autoradiography","volume":"89","author":"Aquilonius","year":"1992","journal-title":"J Neural Transm Gen Sect"},{"key":"10.3233\/JAD-220908_ref55","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/glia.440080208","article-title":"Monoamine oxidase-B in astrocytes","volume":"8","author":"Ekblom","year":"1993","journal-title":"Glia"},{"key":"10.3233\/JAD-220908_ref56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.seizure.2018.07.010","article-title":"Serum GFAP level: A novel adjunctive diagnostic test in differentiate epileptic seizures from psychogenic attacks","volume":"61","author":"Simani","year":"2018","journal-title":"Seizure"},{"key":"10.3233\/JAD-220908_ref57","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clineuro.2011.11.002","article-title":"Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson\u2019s disease patients","volume":"114","author":"Su","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"key":"10.3233\/JAD-220908_ref58","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/jnnp-2018-318868","article-title":"Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase","volume":"90","author":"Oeckl","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-220908_ref59","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3233\/JAD-200608","article-title":"Serum glial fibrillary acidic protein (GFAP) is a marker of disease severity in frontotemporal lobar degeneration","volume":"77","author":"Benussi","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220908_ref60","doi-asserted-by":"crossref","first-page":"e12285","DOI":"10.1002\/dad2.12285","article-title":"Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia","volume":"14","author":"Thijssen","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-220908_ref61","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-328547"},{"key":"10.3233\/JAD-220908_ref62","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1073\/pnas.79.20.6385","article-title":"Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons","volume":"79","author":"Levitt","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-220908_ref63","doi-asserted-by":"crossref","first-page":"807435","DOI":"10.3389\/fnins.2022.807435","article-title":"Imaging of reactive astrogliosis by positron emission tomography","volume":"16","author":"Harada","year":"2022","journal-title":"Front Neurosci"},{"key":"10.3233\/JAD-220908_ref64","doi-asserted-by":"crossref","first-page":"e2026","DOI":"10.1212\/WNL.0000000000009405","article-title":"Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease","volume":"94","author":"Vilaplana","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JAD-220908_ref65","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00259-015-3047-0","article-title":"Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: A correlative positron emission tomography and in vitro imaging study","volume":"42","author":"Rodriguez-Vieitez","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.3233\/JAD-220908_ref66","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1474-4422(19)30282-0","article-title":"Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: A prospective multicentre study","volume":"18","author":"Yue","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220908_ref67","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3389\/fneur.2020.01054","article-title":"Comparing glial fibrillary acidic protein (GFAP) in serum and plasma following mild traumatic brain injury in older adults","volume":"11","author":"Huebschmann","year":"2020","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-220908_ref68","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41398-021-01423-6","article-title":"Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression","volume":"11","author":"Michel","year":"2021","journal-title":"Transl Psychiatry"},{"key":"10.3233\/JAD-220908_ref69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jpsychires.2021.09.012","article-title":"Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder","volume":"144","author":"Steinacker","year":"2021","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JAD-220908_ref70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13195-022-01093-6","article-title":"Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias","volume":"14","author":"Baiardi","year":"2022","journal-title":"Alzheimers Res Ther"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-220908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:16Z","timestamp":1777370836000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-220908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":70,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-220908","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]}}}